hysteroscopic surgery
Conditions
Interventions
Phase I: Experimental Group (T Group):Teglicarpidine combined with remimazolam. The dosage of teglicarpidine for the next patient is dynamically adjusted based on the surgical analgesic effect of the
Phase I: Control Group (S Group):Sufentanil combined with remimazolam. The dosage of sufentanil for the next patient is dynamically adjusted based on the surgical analgesic effect of the previous pati
Phase II: Experimental Group (T Group):Combined with remimazolam, the ED90 of Teglicarpidine obtained by the BCD sequential method in the first phase.
Phase II: Control Group (S Group):Combined with remimazolam, the ED90 of sufentanil obtained by the BCD sequential method in the first phase.
Sponsors
Xiangyang Central Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing elective hysteroscopic surgery; 2. Aged 18-60 years; 3. American Society of Anesthesiologists (ASA) physical status classification ?-II; 4. Body Mass Index (BMI) 18-25 kg/m²; 5. No preoperatively diagnosed respiratory diseases and normal airway assessment.
Exclusion criteria
Exclusion criteria: 1. Refusal to sign the informed consent form; 2. Allergy to the experimental drugs; 3. Abnormal vital signs of clinical significance or abnormal results of clinical laboratory tests; 4. Long-term use of opioids, analgesics, sedatives, or a history of alcoholism; 5. Presence of mental illness or inability to communicate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90% Effective Dose (ED90) of Teglidipine Fumarate Combined with Remimazolam for Hysteroscopic Surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of perioperative respiratory depression;Postoperative NRS score;Satisfaction scores of patients, anesthesiologists, and endoscopists;Hemodynamic parameters (blood pressure and heart rate) at each time point;Intraoperative adverse event rate;Incidence of postoperative nausea and vomiting (PONV); | — |
Countries
China
Contacts
Public ContactQinyi Chen
Xiangyang Central Hospital
Outcome results
None listed